Latest news with #RibbonBio
Time Business News
06-07-2025
- Business
- Time Business News
Enzymatic DNA Synthesis Gains Momentum with Precision & Medical Demand
Enzymatic DNA synthesis is a contemporary technique for producing synthetic DNA, using enzymes (biological catalysts) instead of more conventional chemical techniques (such as phosphoramidite synthesis). Enzymatic DNA synthesis has a number of important advantages as compared to conventional chemical techniques. Need for precise and effective DNA synthesis techniques has grown in recent years due to developments in synthetic biology and gene editing technologies notably CRISPR-Cas9. Major focus on personalized medicine, where customized DNA sequences are important for creating customized treatments, raises this demand. With growing incidence of chronic illnesses and the search for modern treatment options that includes gene therapy are major factors for market expansion on global scale. Key Growth Drivers and Opportunities Rising Incidence of Chronic Diseases: The potential measure of the increasing cases of chronic diseases such as cancer, genetic abnormalities, and cardiovascular ailments, the enzymatic DNA synthesis is commonly known and has grown. Given treatment has ability to produce tailored DNA sequences rapidly and precisely, which is crucial for the development of targeted medications, gene treatments, and molecular diagnostics. As healthcare systems shift towards accurate medicine to better manage chronic illnesses, the need for scalable DNA synthesis technologies is estimated to increase which will drive market expansion on global scale. Challenges Major disadvantage includes the enzymatic DNA synthesis that is unable to accurately produce lengthy DNA sequences. There are difficulties regarding the enzymatic procedures that frequently encounter with premature termination, misincorporation of bases, or structural instability of larger chains, in contrast to conventional chemical methods that can consistently manufacture longer strands through stepwise nucleotide addition. This factor limits the adoption of enzymatic DNA synthesis in big gene constructs. Innovation and Expansion Ribbon Bio Unveils MiroSynth DNA Molecules In May 2025, MiroSynth DNA was launched by Ribbon Bio which marks it as first commercial product in enzymatic DNA synthesis that is designed for DNA construction that is complex and high accuracy of product target applications across biopharma, life sciences, and academic research. Major market including the U.S., EU, UK, and Australia has access to MiroSynth. This launch was termed as 'a defining milestone' as the given technology focus on algorithm-driven precision enzymatic assembly and supports both linear and circular DNA formats. Ansa Biotechnologies Sets New Long-DNA Record In November 2024, Ansa Clonal DNA was introduced by Ansa Biotechnologies that is able to deliver sequence-perfect clonal DNA up to 5 kilobases. It allows the synthesis of complex DNA with high GC content, hairpins, and repeat regions. Ansa clonal DNA is built on its proprietary sequence-agnostic enzymatic assembly platform and advanced long-read quality control pipeline. Ansa clonal DNA had its first-pass delivery of challenging constructs according to initial user reports. Given product will make a major impact on research in protein engineering, neuroscience, and therapeutic development. Molecular Assemblies Launches On-Site FES Partner Program In May 2024, a new Partnering Program was launched by Molecular Assemblies to license its Fully Enzymatic Synthesis (FES) technology for in-house use. This was one step ahead to decentralized DNA synthesis, giving researchers direct access to long, accurate, and pure DNA production without outsourcing. This modification aims to provide adequate synthesis capabilities to labs working on synthetic biology, biotherapeutics, and diagnostics. FES technology replicates nature's writing in DNA using an ecologically safe, water-based enzymatic process. Inventive Sparks, Expanding Markets The key companies for enzymatic DNA synthesis are Evonetix, DNA TwoPointO, Inc., GenScript, TELESIS BIO INC., DNA Script, and others. Establishment of strategic alliances and partnerships with biotech firms, educational institutions, and research groups in order to boost innovation and broaden application areas are major focus of these key players propelling the enzymatic DNA synthesis (EDS) market's expansion. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
06-05-2025
- Business
- Yahoo
Ribbon Bio Launches MiroSynth™ DNA Molecules to Unlock a New Era of Complex Synthetic DNA
First Commercial Offering Delivers Complex, Long, and Highly Accurate DNA to Power Transformative Scientific Breakthroughs VIENNA, May 06, 2025--(BUSINESS WIRE)--Ribbon Bio GmbH, the DNA synthesis company, today announced the launch of MiroSynth™ DNA, its first commercial product designed to meet the growing demand for complex and highly-accurate synthetic DNA molecules. The product launch coincides with the Global Synthetic Biology Conference in San Jose, California, taking place May 5–8, 2025. MiroSynth™ DNA is built on Ribbon's proprietary algorithm-driven technology and precision enzymatic assembly process, delivering exceptional accuracy and performance for applications initially in biopharma, life sciences and academic research. Customers and partners across the US, EU, UK, and Australia can now access MiroSynth™ DNA to accelerate their most ambitious scientific work. "This is a defining milestone for Ribbon Bio as we commercialize synthetic DNA at the highest levels of complexity and accuracy," said Jodi Barrientos, CEO of Ribbon Bio. "MiroSynth™ DNA offers unmatched quality for researchers developing next-generation solutions in therapeutics, life sciences, and beyond. We're proud to serve scientists who are pushing the boundaries of possibility today." Engineered to meet the increasing need for more complex and highly accurate DNA at length, MiroSynth™ DNA is available in both linear and circular formats. The name MiroSynth—inspired by the Latin word for extraordinary—reflects the product's potential to transform scientific possibilities by overcoming long-standing limitations in DNA synthesis and assembly. Ribbon Bio will showcase MiroSynth™ DNA at the Global Synthetic Biology Conference 2025, where the company is a sponsor. On May 6, Ribbon will participate in two featured sessions: CEO Jodi Barrientos will host a Spotlight Session on Ribbon's end-to-end DNA synthesis platform, highlighting the integration of intelligent algorithms, enzymatic assembly, adaptive automation, and full traceability from sequence to molecule. CTO Dr. John Luckey will join a panel exploring how complex synthetic DNA is reshaping the future of science and innovation. About Ribbon Bio Ribbon Bio is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies: making the impossible possible. We are redefining scientific possibility with our algorithm-driven technology that produces pristine synthetic DNA molecules, at a high level of accuracy and unprecedented speed, enabling our partners to deliver a new generation of transformative solutions for the health of people and the planet. For more information, visit us at
Business Wire
06-05-2025
- Business
- Business Wire
Ribbon Bio Appoints Jeff Fitzgerald as Vice President, Global Head of Sales to Drive Commercial Growth and Strategic Expansion
VIENNA--(BUSINESS WIRE)--Ribbon Bio GmbH, the DNA synthesis company, today announced that Jeff Fitzgerald has joined the company as Vice President, Global Head of Sales. With a proven track record in scaling commercial operations and leading teams across the industry, Mr. Fitzgerald will take on a pivotal role in accelerating Ribbon Bio's next phase of growth. 'We're thrilled to welcome Jeff to the Ribbon Bio leadership team at this important time, as we commence our exciting first product launch with MiroSynth™ DNA Molecules,' said Jodi Barrientos, CEO. Reporting directly to Jodi Barrientos, Ribbon's CEO, Mr. Fitzgerald will oversee all aspects of global sales strategy, business development, and market expansion as the company commercializes its technology to produce pristine synthetic DNA molecules to serve advanced applications in biopharma and life sciences. 'We're thrilled to welcome Jeff to the Ribbon Bio leadership team at this important time, as we commence our exciting first product launch with MiroSynth™ DNA Molecules,' said Ms. Barrientos. 'His deep industry experience and customer-first approach make him the ideal leader to help drive our commercial strategy forward, especially as global demand for more complex and highly accurate synthetic DNA continues to rise.' Mr. Fitzgerald brings more than a decade of successful commercial leadership experience in life science companies, including executive roles at ArcherDx (acquired by Integrated DNA Technologies (IDT)), and IQVIA (formerly Quintiles), where he led high-performing teams, delivered sustained revenue growth across multiple geographies, and supported commercial integrations post-merger and acquisition. His expertise in product launches, building strategic partnerships and scaling go-to-market operations aligns well with Ribbon Bio's mission to redefine what's possible in synthetic biology through precision-engineered DNA. 'I'm very excited to join Ribbon Bio at such a transformative moment,' said Mr. Fitzgerald. 'The company's ability to deliver highly complex and accurate synthetic DNA is unmatched—and I'm looking forward to supporting our partners to bring their most ambitious biological designs to life with MiroSynth™ DNA Molecules.' MiroSynth™ DNA is built on Ribbon's proprietary algorithm-driven technology and precision enzymatic assembly process, delivering exceptional accuracy and performance for applications initially in biopharma, life sciences, and academic research. Customers and partners across the US, EU, UK, and Australia can now access MiroSynth™ DNA to accelerate their most ambitious scientific work. This strategic hire follows a year of significant momentum for Ribbon Bio, including key leadership additions, major partnerships in biopharma and life sciences, demonstrated technical advances in its core platform, and growing global demand for synthetic DNA at the highest levels of complexity and precision. About Ribbon Bio Ribbon Bio is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies: making the impossible possible. We are redefining scientific possibility with our algorithm-driven technology that produces pristine synthetic DNA molecules, at a high level of accuracy and unprecedented speed, enabling our partners to deliver a new generation of transformative solutions for the health of people and the planet. For more information, visit us at
